Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.

Abstract : ABSTRACT: BACKGROUND: "Evergreening" refers to the numerous strategies whereby owners of pharmaceutical products use patent laws and minor drug modifications to extend their monopoly privileges on the drug. We aimed to evaluate the impact of evergreening through the case study of the antidepressant citalopram and its chiral switch form escitalopram by evaluating treatment efficacy and acceptability for patients, as well as health insurance costs for society. METHODS: To assess efficacy and acceptability, we performed meta-analyses for efficacy and acceptability. We compared direct evidence (meta-analysis of results of head-to-head trials) and indirect evidence (adjusted indirect comparison of results of placebo-controlled trials). To assess health insurance costs, we analyzed individual reimbursement data from a representative sample of the French National Health Insurance Inter-regime Information System (SNIIR-AM) from 2003 to 2010, which allowed for projecting these results to the whole SNIIR-AM population (53 million people). RESULTS: In the meta-analysis of seven head-to-head trials (2,174 patients), efficacy was significantly better for escitalopram than citalopram (combined odds ratio (OR) 1.60 (95% confidence interval 1.05 to 2.46)). However, for the adjusted indirect comparison of 10 citalopram and 12 escitalopram placebo-controlled trials, 2,984 and 3,777 patients respectively, efficacy was similar for the two drug forms (combined indirect OR 1.03 (0.82 to 1.30)). Because of the discrepancy, we could not combine direct and indirect data (test of inconsistency, P = 0.07). A similar discrepancy was found for treatment acceptability. The overall reimbursement cost burden for the citalopram, escitalopram and its generic forms was 120.6 million Euros in 2010, with 96.8 million Euros for escitalopram. CONCLUSIONS: The clinical benefit of escitalopram versus citalopram remains uncertain. In our case of evergreening, escitalopram represented a substantially high proportion of the overall reimbursement cost burden as compared with citalopram and the generic forms.
Type de document :
Article dans une revue
BMC Medicine, BioMed Central, 2012, 10 (1), pp.142. 〈10.1186/1741-7015-10-142〉
Liste complète des métadonnées

Littérature citée [37 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00764321
Contributeur : Ed. Bmc <>
Soumis le : mercredi 12 décembre 2012 - 17:09:59
Dernière modification le : vendredi 22 décembre 2017 - 09:44:02
Document(s) archivé(s) le : mercredi 13 mars 2013 - 03:56:57

Identifiants

Collections

Citation

Ali Alkhafaji, Ludovic Trinquart, Gabriel Baron, Moïse Desvarieux, Philippe Ravaud. Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.. BMC Medicine, BioMed Central, 2012, 10 (1), pp.142. 〈10.1186/1741-7015-10-142〉. 〈inserm-00764321〉

Partager

Métriques

Consultations de la notice

520

Téléchargements de fichiers

219